Deep Vein Thrombosis (DVT) News and Research

RSS

Discovery of biomarkers that can influence COVID-19 severity

The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.

19 Jun 2020

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.

5 Jun 2020

Deep vein clots in critical COVID-19 illness

A new research paper published in the journal JAMA Network Open in May 2020 reports a high incidence of deep vein clots in patients with severe COVID-19 at a single French medical center. This could indicate the need for systematic anticoagulant therapy in these patients as a preventive measure.

31 May 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Research could offer new hope for the prevention, treatment of deep vein thrombosis

New University of Birmingham research funded by the British Heart Foundation could improve treatments for a potentially deadly condition that affects tens of thousands of people in the UK each year.

26 Nov 2019

New study provides better understanding of blood clot formation in cancer patients

Researchers have identified a potential new signaling pathway that may help further the understanding of blood clot formation in cancer patients and ultimately help prevent this complication from occurring.

22 Nov 2019

Herbal medicine for preventing, healing vascular diseases

The system connects the arteries to the veins. There are 100,000 miles of blood vessels in the adult human body.

30 Jul 2019

HORIBA Medical introduces D-Dimer reagent for Yumizen G hemostasis range

HORIBA UK Ltd, Medical announces the launch of a D-Dimer parameter for its Yumizen G hemostasis range of instruments.

From HORIBA Medical 25 Mar 2019

New clinical practice guidelines for managing venous thromboembolism released

Venous thromboembolism, a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death.

28 Nov 2018

Immediate compression therapy could cut risk of complications after deep-vein thrombosis

People with deep-vein thrombosis can substantially cut their risk of potentially debilitating complications by starting adequate compression therapy in the first twenty-four hours of DVT therapy (known as the acute phase of treatment), suggests a study published today in the journal Blood.

20 Sep 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

Oral drug reduces venous thromboembolism recurrence among cancer patients

Research from the University of Warwick indicates that taking a tablet a day can help treat cancer patients of a potentially deadly condition.

11 May 2018

Anti-allergy medicines may be effective treatment for deadly blood clots in the legs

Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.

2 Aug 2017

YouGov survey reveals risks of DVT during long-haul flights

Almost a quarter of UK adults will fly long-haul (over four hours) on holiday or business this year, but are perhaps unaware that one in 25 will suffer an asymptomatic deep vein thrombosis (DVT).

7 Jul 2017

Inferior vena cava filters may be overused in managed care populations, study suggests

Humana Inc. today announced research findings that suggest inferior vena cava (IVC) filters may be overused in managed care populations, and that filters may not always be removed after they are no longer needed.

6 Jul 2017

Reducing DVT and leg ulcers through personalized compression socks

Professor Charles McCollum, who heads up the vascular studies unit, is a research vascular surgeon, and he developed four-layer bandaging technique, which is the gold standard treatment for healing up leg ulcers by compression.

5 Jul 2017

Researchers identify sex-based differences in utilization, safety outcomes of CDT for treatment of DVT

Deep vein thrombosis (DVT) is a serious condition that occurs when a blood clot forms in a vein, often in the deep veins of the legs, thigh or pelvis. Those clots can break loose, travel to the lungs and block blood flow, causing a pulmonary embolism.

21 Mar 2017

Genotype-guided warfarin dosing linked to reduced risk of adverse events

Using genetic testing to help personalize doses of warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with clinically guided dosing, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.